▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1148 by analyst upside · 2026-11-13
KROS
Keros Therapeutics, Inc.
Healthcare · Market Cap $198M · P/E 0x
ANALYST PRICE TARGET
+96.8%
implied upside to consensus target
Current Price $10.08
Consensus Target $19.83
Bull Target $25.0
Bear Target $16.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
3
Hold
3
Sell
0
52-Week Low $8.98
52-Week High $22.55
YTD Return -45.6%
FUNDAMENTALS
Market Cap $198M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.32
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $41M
Profit Margin -151.4%
52-WEEK RANGE
52-Week Low $8.98
52-Week High $22.55
Current Price $10.08
Bear Target $16.0
Bull Target $25.0
● Now $10.08 ● Target $19.83
TRADING DATA
Avg Volume 181K
YTD Return -45.6%
Analyst Count 6
Consensus Buy
Upside to Target +96.8%
Last Updated 2026-11-13

ANALYST SUMMARY

Keros Therapeutics, Inc. (KROS) is currently trading at $10.08 with a Wall Street consensus price target of $19.83, implying potential upside of 96.8% over the next 12 months. 6 analysts currently cover KROS, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $25.0, while the most cautious has a target of $16.0.

KROS operates in the Healthcare sector with a market capitalisation of $198M. The stock is down 45.6% year-to-date and is currently trading near the lower end of its 52-week range of $8.98 – $22.55.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CGEN +126.4%
Compugen Ltd.
$201M · P/E 5.4x · Buy
ORMP +73.7%
Oramed Pharmaceuticals Inc.
$168M · P/E 1.0x · Hold
ELMD +94.2%
Electromed, Inc.
$204M · P/E 18.1x · Buy
PDEX +9.8%
Pro-Dex, Inc.
$216M · P/E 18.6x · Buy
WW +124.1%
WW International, Inc.
$123M · P/E 0.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for KROS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo - Reiterated
Overweight → Overweight 2026-08-04 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-08-04 29% win rate (7 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-03-05 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2025-11-28 Building track record
Oppenheimer reit
Outperform → Outperform 2025-11-12 14% win rate (7 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2025-11-11 Building track record
Wedbush - Reiterated
Neutral → Neutral 2025-11-06 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-08-08 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
34
out of 100
Coverage depth
15/30
Consensus clarity
12/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →